Probiotics and prevention of Clostridium difficile infection.

[1]  M. Jit,et al.  The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy. , 2016, Vaccine.

[2]  B. Johnston,et al.  Probiotics and the Prevention of Antibiotic-Associated Diarrhea in Infants and Children. , 2016, JAMA.

[3]  L. Mcfarland.  An observation on inappropriate probiotic subgroup classifications in the meta-analysis by Lau and Chamberlain , 2016, International journal of general medicine.

[4]  Mark A. Miller,et al.  Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  B. Manns,et al.  Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile–Associated Diarrhea in a Provincial Healthcare System , 2016, Infection Control & Hospital Epidemiology.

[6]  J. Jernigan,et al.  Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. , 2016, American journal of infection control.

[7]  H. Gary,et al.  Contribution of Contact Sampling in Increasing Sensitivity of Poliovirus Detection During A Polio Outbreak—Somalia, 2013 , 2016, Open forum infectious diseases.

[8]  L. Valiquette,et al.  Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  P. Coyte,et al.  Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection , 2016, PloS one.

[10]  M. Keuchel,et al.  Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial , 2016, Open forum infectious diseases.

[11]  H. Szajewska,et al.  Systematic review with meta‐analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic‐associated diarrhoea in children and adults , 2015, Alimentary pharmacology & therapeutics.

[12]  M. Millette,et al.  Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  W. Trick,et al.  Pathway to Prevention of Nosocomial Clostridium difficile Infection. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Nasia Safdar,et al.  Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Snydman,et al.  Risk and safety of probiotics. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  E. Goldstein,et al.  A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Evans,et al.  Prevention of Clostridium difficile Infection With Probiotics. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  L. Mcfarland.  From yaks to yogurt: the history, development, and current use of probiotics. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  E. Goldstein,et al.  Lactobacillus species: taxonomic complexity and controversial susceptibilities. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Ren,et al.  Survival of Lactobacillus casei strain Shirota in the intestines of healthy Chinese adults , 2015, Microbiology and immunology.

[21]  P. Barnes,et al.  Trends in the use of complementary health approaches among adults: United States, 2002-2012. , 2015, National health statistics reports.

[22]  E. Goldstein,et al.  Clostridium difficile: improving the prevention paradigm in healthcare settings , 2014, Expert review of anti-infective therapy.

[23]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[24]  M. Pimentel,et al.  Probiotics for antibiotic-associated diarrhea: PLACIDE swings the pendulum. , 2014, Gastroenterology.

[25]  M. Shrime,et al.  Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  T. Klaenhammer,et al.  Impact of genomics on the field of probiotic research: historical perspectives to modern paradigms , 2014, Antonie van Leeuwenhoek.

[27]  M. P. Bauer,et al.  European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  E. Goldstein,et al.  Bacterial counts from five over-the-counter probiotics: are you getting what you paid for? , 2014, Anaerobe.

[29]  Michael B Gravenor,et al.  Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial , 2013, The Lancet.

[30]  B. Currie,et al.  Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital , 2013, Current medical research and opinion.

[31]  G. Guyatt,et al.  Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. , 2013, The Cochrane database of systematic reviews.

[32]  R. Hunt,et al.  Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[33]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[34]  W. Trick,et al.  Is primary prevention of Clostridium difficile infection possible with specific probiotics? , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[35]  D. Gerding,et al.  Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Nayoung Kim,et al.  World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. , 2012, Journal of clinical gastroenterology.

[37]  S. Salminen,et al.  Manufacturing process influences properties of probiotic bacteria , 2010, British Journal of Nutrition.

[38]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.

[39]  J. Sampalis,et al.  Efficacy of BIO K+ CL1285® in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study , 2010, Archives of medical science : AMS.

[40]  L. Miller,et al.  Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients , 2010, The American Journal of Gastroenterology.

[41]  L. Mcfarland.  Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. , 2009, Anaerobe.

[42]  Stuart Johnson.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.

[43]  J. Lachaine,et al.  Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[44]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[45]  J. Pépin,et al.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  Matthew R. Thomas,et al.  Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. , 2001, Mayo Clinic proceedings.

[47]  C. Surawicz,et al.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  C. Surawicz,et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.

[49]  S. Gorbach.  Probiotics and gastrointestinal health. , 2000, The American journal of gastroenterology.

[50]  B. Goldin,et al.  Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. , 1987, Journal of dairy science.